Global Chimeric Antigen Receptor (CAR) T-Cell Therapy: Industry Analysis & Outlook (2019-2023)
CAR-T cell therapy is the most promising and remarkable treatment in the areas of oncology. It is a treatment that uses cells from a person’s own immune system to fight against cancer. CAR-T Cell therapy works on gene transfer technology that enhances the immune response of cancer affected patient by destroying tumor cells. In 2017, two CAR-T Cell therapies were approved by the Food and Drug Administration (FDA), one for the treatment of children with acute lymphoblastic leukemia (ALL) and the other for adults with advanced lymphomas.
CAR-T Cell market is majorly driven by an increasing number of cancer cases and high demand for effective therapy in this area. The increasing number of products in the clinical pipeline under development would act as a growth catalyst for the global market. The ability of therapy to treat recurrent cancers with high efficiency is also contributing significantly to the market growth.
CD19 is the most targeted antigen for a limited range of blood cancers. Hematological cancers indicate a highly competitive therapy segment as compared to solid tumors, in which it is little difficult to identify the antigens and will offer a vast market potential. With the recent launch of CAR-T cell therapies like Kymriah and Yescarta, the market is estimated to witness robust growth in the upcoming years.
The market exhibit huge potential for companies engaged in developing, manufacturing of CAR T cell therapies for cancer treatment. Upcoming novel products and technologies and the presence of big players in the market will result in intense competition in future.
The report “Global CAR-T Cell Market: Industry Analysis & Outlook (2019-2023)” by Koncept Analytics provides extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering The United States, Europe, and Japan region along with the global market. The report profiles the key players of the market including Novartis International AG, Bluebird Bio, Celgene Corporation and Gilead Sciences.
CAR-T Cell market is majorly driven by an increasing number of cancer cases and high demand for effective therapy in this area. The increasing number of products in the clinical pipeline under development would act as a growth catalyst for the global market. The ability of therapy to treat recurrent cancers with high efficiency is also contributing significantly to the market growth.
CD19 is the most targeted antigen for a limited range of blood cancers. Hematological cancers indicate a highly competitive therapy segment as compared to solid tumors, in which it is little difficult to identify the antigens and will offer a vast market potential. With the recent launch of CAR-T cell therapies like Kymriah and Yescarta, the market is estimated to witness robust growth in the upcoming years.
The market exhibit huge potential for companies engaged in developing, manufacturing of CAR T cell therapies for cancer treatment. Upcoming novel products and technologies and the presence of big players in the market will result in intense competition in future.
The report “Global CAR-T Cell Market: Industry Analysis & Outlook (2019-2023)” by Koncept Analytics provides extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering The United States, Europe, and Japan region along with the global market. The report profiles the key players of the market including Novartis International AG, Bluebird Bio, Celgene Corporation and Gilead Sciences.
1. MARKET OVERVIEW
1.1 Introduction
1.2 CAR-T Cell Design
1.3 Process of T-Cell Therapy
1.4 Autologous vs. Allogeneic CAR-T cell therapy
1.5 Mechanism of Action
1.6 Toxicity Related to CAR-T Cell Therapy
1.7 FDA Approved CAR-T Cell Therapy
1.8 CAR-T Cell Therapies under Development
2. GLOBAL MARKET ANALYSIS
2.1 Global CAR-T Cell Market Forecast by Value
2.2 Number of CAR-T Cell Clinical Trials
2.3 Number of Clinical Trials Targeting Hematologic Malignancies by Antigens
2.4 Number of Clinical Trials Targeting Solid Tumors by Antigens
2.5 Global CAR-T Cell Hematological Malignancy Market
2.5.1 Global CAR-T Cell Hematological Malignancy Market Share by Cancer Type
2.5.2 Global CAR-T Cell Hematological Malignancy Market Share Forecast by Cancer Type
2.5.3 Global CAR-T Cell ALL Market Forecast by Value
2.5.4 Global CAR-T Cell DLBCL Market Forecast by Value
2.5.5 Global CAR T Cell FL Market Forecast by Value
2.5.6 Global CAR-T Cell CLL Market Forecast by Value
2.5.7 Global CAR T Cell MM Market Forecast by Value
2.6 Global Kymriah Revenue Forecast
2.7 Global Yescarta Revenue Forecast
2.8 Global CYAD-01 AML Revenue Forecast
2.9 Global CYAD-01 mCRC Revenue Forecast
3. REGIONAL MARKET ANALYSIS
3.1 The U.S.
3.1.1 The U.S. ALL Patients Treated with UCART19 Forecast
3.1.2 The U.S. UCART19 Revenue Forecast
3.1.3 The U.S. DLBCL Patients Treated with ALLO-501 Forecast
3.1.4 The U.S. ALLO-501 Revenue Forecast
3.1.5 The U.S. Patients treated with CYAD-01 for AML Forecast
3.1.6 The U.S. CYAD-01 Revenue Forecast for AML
3.1.7 The U.S. Patients Treated with CYAD-01 for mCRC Forecast
3.1.8 The U.S. CYAD-01 Revenue for mCRC Forecast
3.2 Europe
3.2.1 Europe Patients Treated with CYAD-01 for AML Forecast
3.2.2 Europe CYAD-01 Revenue for AML Forecast
3.2.3 Europe Patients treated with CYAD-01 for mCRC Forecast
3.2.4 Europe CYAD-01 Revenue for mCRC Forecast
3.3 Japan
3.3.1 Japan Patients treated with CYAD-01 for AML Forecast
3.3.2 Japan CYAD-01 Revenue for AML Forecast
3.3.3 Japan Patients treated with CYAD-01 for mCRC Forecast
3.3.4 Japan CYAD-01 Revenue for mCRC Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Growing Cancer Incidences Rates
4.1.2 Proven Effectiveness of T-cell Therapies
4.1.3 Increasing Number of Deals for CART cell Development
4.1.4 High Unmet Needs
4.2 Key Trends & Developments
4.2.1 Collaborative R&D
4.2.2 Reimbursements
4.3 Challenges
4.3.1 High Cost
4.3.2 Regulatory Standards
4.3.3 Safety Concerns
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 Global CART Cell Therapies in AML under Development
5.1.3 Global CAR-T under Development for Metastatic Colorectal Cancer
5.1.4 Global BCMA CAR T Therapies in Clinical Trials for Multiple Myeloma
5.1.5 Global CD19 targeted CART products in Clinical Trials
5.1.6 Global CD19 targeted CART products in Clinical Trials for Adult ALL
6. COMPANY PROFILES
6.1 Bluebird Bio, Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Celgene Corporation
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Novartis International AG
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Gilead Sciences
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Introduction
1.2 CAR-T Cell Design
1.3 Process of T-Cell Therapy
1.4 Autologous vs. Allogeneic CAR-T cell therapy
1.5 Mechanism of Action
1.6 Toxicity Related to CAR-T Cell Therapy
1.7 FDA Approved CAR-T Cell Therapy
1.8 CAR-T Cell Therapies under Development
2. GLOBAL MARKET ANALYSIS
2.1 Global CAR-T Cell Market Forecast by Value
2.2 Number of CAR-T Cell Clinical Trials
2.3 Number of Clinical Trials Targeting Hematologic Malignancies by Antigens
2.4 Number of Clinical Trials Targeting Solid Tumors by Antigens
2.5 Global CAR-T Cell Hematological Malignancy Market
2.5.1 Global CAR-T Cell Hematological Malignancy Market Share by Cancer Type
2.5.2 Global CAR-T Cell Hematological Malignancy Market Share Forecast by Cancer Type
2.5.3 Global CAR-T Cell ALL Market Forecast by Value
2.5.4 Global CAR-T Cell DLBCL Market Forecast by Value
2.5.5 Global CAR T Cell FL Market Forecast by Value
2.5.6 Global CAR-T Cell CLL Market Forecast by Value
2.5.7 Global CAR T Cell MM Market Forecast by Value
2.6 Global Kymriah Revenue Forecast
2.7 Global Yescarta Revenue Forecast
2.8 Global CYAD-01 AML Revenue Forecast
2.9 Global CYAD-01 mCRC Revenue Forecast
3. REGIONAL MARKET ANALYSIS
3.1 The U.S.
3.1.1 The U.S. ALL Patients Treated with UCART19 Forecast
3.1.2 The U.S. UCART19 Revenue Forecast
3.1.3 The U.S. DLBCL Patients Treated with ALLO-501 Forecast
3.1.4 The U.S. ALLO-501 Revenue Forecast
3.1.5 The U.S. Patients treated with CYAD-01 for AML Forecast
3.1.6 The U.S. CYAD-01 Revenue Forecast for AML
3.1.7 The U.S. Patients Treated with CYAD-01 for mCRC Forecast
3.1.8 The U.S. CYAD-01 Revenue for mCRC Forecast
3.2 Europe
3.2.1 Europe Patients Treated with CYAD-01 for AML Forecast
3.2.2 Europe CYAD-01 Revenue for AML Forecast
3.2.3 Europe Patients treated with CYAD-01 for mCRC Forecast
3.2.4 Europe CYAD-01 Revenue for mCRC Forecast
3.3 Japan
3.3.1 Japan Patients treated with CYAD-01 for AML Forecast
3.3.2 Japan CYAD-01 Revenue for AML Forecast
3.3.3 Japan Patients treated with CYAD-01 for mCRC Forecast
3.3.4 Japan CYAD-01 Revenue for mCRC Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Growing Cancer Incidences Rates
4.1.2 Proven Effectiveness of T-cell Therapies
4.1.3 Increasing Number of Deals for CART cell Development
4.1.4 High Unmet Needs
4.2 Key Trends & Developments
4.2.1 Collaborative R&D
4.2.2 Reimbursements
4.3 Challenges
4.3.1 High Cost
4.3.2 Regulatory Standards
4.3.3 Safety Concerns
5. COMPETITIVE LANDSCAPE
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 Global CART Cell Therapies in AML under Development
5.1.3 Global CAR-T under Development for Metastatic Colorectal Cancer
5.1.4 Global BCMA CAR T Therapies in Clinical Trials for Multiple Myeloma
5.1.5 Global CD19 targeted CART products in Clinical Trials
5.1.6 Global CD19 targeted CART products in Clinical Trials for Adult ALL
6. COMPANY PROFILES
6.1 Bluebird Bio, Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Celgene Corporation
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Novartis International AG
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Gilead Sciences
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF FIGURES
CAR-T Cell Formation
Mechanism of Car-T cell Therapy
Global CAR-T Cell Market Forecast by Value (2018-2023)
Number of CAR-T Cell Clinical Trials (2013-2017)
Number of Clinical Trials Targeting Hematologic Malignancies by Antigens (2017)
Number of Clinical Trials Targeting Solid Tumors by Antigens (2017)
Global CAR-T Cell Hematological Malignancy Market Forecast (2018-2023)
Global CAR-T Cell Hematological Malignancy Market Share by Cancer Type (2018)
Global CAR-T Cell Hematological Malignancy Market Share Forecast by Cancer Type (2023)
Global CAR-T Cell ALL Market Forecast by Value (2018-2023)
Global CAR-T Cell DLBCL Market Forecast by Value (2018-2023)
Global CAR T Cell FL Market Forecast by Value (2019-2023)
Global CAR T Cell CLL Market Forecast by Value (2019-2023)
Global CAR T Cell MM Market Forecast by Value (2019-2023)
Global Kymriah Revenue Forecast (2018-2023)
Global Yescarta Revenue Forecast (2018-2023)
Global CYAD-01 AML Revenue Forecast (2023-2028)
Global CYAD-01 mCRC Revenue Forecast (2024-2028)
The U.S. ALL Patients Treated with UCART19 Forecast (2018-2023)
The U.S. UCART19 Revenue Forecast (2023-2027)
The U.S. DLBCL Patients Treated with ALLO-501 Forecast (2018-2023)
The U.S. ALLO-501 Revenue Forecast (2023-2027)
The U.S. Patients treated with CYAD-01 for AML Forecast (2023-2028)
The U.S. CYAD-01 Revenue Forecast for AML (2023-2028)
The U.S. Patients Treated with CYAD-01 for mCRC Forecast (2024-2029)
The U.S. CYAD-01 Revenue for mCRC Forecast (2024-2028)
Europe Patients Treated with CYAD-01 for AML Forecast (2023-2028)
Europe CYAD-01 Revenue for AML Forecast (2023-2028)
Europe Patients treated with CYAD-01 for mCRC Forecast (2024-2028)
Europe CYAD-01 Revenue for mCRC Forecast (2024-2028)
Japan Patients treated with CYAD-01 for AML Forecast (2025-2028)
Japan CYAD-01 Revenue for AML Forecast (2025-2028)
Japan Patients treated with CYAD-01 for mCRC Forecast (2024-2028)
Japan CYAD-01 Revenue for mCRC Forecast (2024-2027)
Number of New Cancer Cases by Type (2018)
Clinical Outcomes of Trial Evaluating CAR-T Cells in Blood Cancers (2017)
Bluebird Bio, Inc. Product Pipeline (2018)
Bluebird Bio, Inc. Revenue and Net Loss (2014-2018)
Bluebird Bio, Inc. R&D Expenditure (2016-2018)
Celgene Corporation Revenue by Product Sales (2018)
Celgene Corporation Revenue and Net Income (2014-2018)
Celgene Corporation R&D Expenditure (2016-2018)
Novartis International AG Sales by Segment (2018)
Novartis Net Sales and Net Income (2014-2018)
Gilead Sciences Revenue by Geographical Region (2018)
Gilead Sciences Revenue and Net Income (2014-2018)
Gilead Sciences R&D Expenditure (2016-2018)
CAR-T Cell Formation
Mechanism of Car-T cell Therapy
Global CAR-T Cell Market Forecast by Value (2018-2023)
Number of CAR-T Cell Clinical Trials (2013-2017)
Number of Clinical Trials Targeting Hematologic Malignancies by Antigens (2017)
Number of Clinical Trials Targeting Solid Tumors by Antigens (2017)
Global CAR-T Cell Hematological Malignancy Market Forecast (2018-2023)
Global CAR-T Cell Hematological Malignancy Market Share by Cancer Type (2018)
Global CAR-T Cell Hematological Malignancy Market Share Forecast by Cancer Type (2023)
Global CAR-T Cell ALL Market Forecast by Value (2018-2023)
Global CAR-T Cell DLBCL Market Forecast by Value (2018-2023)
Global CAR T Cell FL Market Forecast by Value (2019-2023)
Global CAR T Cell CLL Market Forecast by Value (2019-2023)
Global CAR T Cell MM Market Forecast by Value (2019-2023)
Global Kymriah Revenue Forecast (2018-2023)
Global Yescarta Revenue Forecast (2018-2023)
Global CYAD-01 AML Revenue Forecast (2023-2028)
Global CYAD-01 mCRC Revenue Forecast (2024-2028)
The U.S. ALL Patients Treated with UCART19 Forecast (2018-2023)
The U.S. UCART19 Revenue Forecast (2023-2027)
The U.S. DLBCL Patients Treated with ALLO-501 Forecast (2018-2023)
The U.S. ALLO-501 Revenue Forecast (2023-2027)
The U.S. Patients treated with CYAD-01 for AML Forecast (2023-2028)
The U.S. CYAD-01 Revenue Forecast for AML (2023-2028)
The U.S. Patients Treated with CYAD-01 for mCRC Forecast (2024-2029)
The U.S. CYAD-01 Revenue for mCRC Forecast (2024-2028)
Europe Patients Treated with CYAD-01 for AML Forecast (2023-2028)
Europe CYAD-01 Revenue for AML Forecast (2023-2028)
Europe Patients treated with CYAD-01 for mCRC Forecast (2024-2028)
Europe CYAD-01 Revenue for mCRC Forecast (2024-2028)
Japan Patients treated with CYAD-01 for AML Forecast (2025-2028)
Japan CYAD-01 Revenue for AML Forecast (2025-2028)
Japan Patients treated with CYAD-01 for mCRC Forecast (2024-2028)
Japan CYAD-01 Revenue for mCRC Forecast (2024-2027)
Number of New Cancer Cases by Type (2018)
Clinical Outcomes of Trial Evaluating CAR-T Cells in Blood Cancers (2017)
Bluebird Bio, Inc. Product Pipeline (2018)
Bluebird Bio, Inc. Revenue and Net Loss (2014-2018)
Bluebird Bio, Inc. R&D Expenditure (2016-2018)
Celgene Corporation Revenue by Product Sales (2018)
Celgene Corporation Revenue and Net Income (2014-2018)
Celgene Corporation R&D Expenditure (2016-2018)
Novartis International AG Sales by Segment (2018)
Novartis Net Sales and Net Income (2014-2018)
Gilead Sciences Revenue by Geographical Region (2018)
Gilead Sciences Revenue and Net Income (2014-2018)
Gilead Sciences R&D Expenditure (2016-2018)
LIST OF TABLES
Comparison between Autologous and Allogeneic T-cell Therapy
Kymriah Developmental Program
Yescarta Developmental Program
Global CAR-T Cell Therapies under Development
Recent Acquisitions in CAR T cell Market (2018)
Recent Collaborations in CAR T cell Market (2018)
CAR-T Cell Treatment Costs (2018)
Key Players - Revenue & Market Cap Comparison (2018)
Global CART Cell Therapies in AML under Development (2018)
Global CAR-T under Development for Metastatic Colorectal Cancer (2018)
Global BCMA CAR T Therapies in Clinical Trials for Multiple Myeloma (2018)
Global CD19 targeted CART products in Clinical Trials (2018)
Global CD19 targeted CART products in Clinical Trials for Adult ALL (2018)
Comparison between Autologous and Allogeneic T-cell Therapy
Kymriah Developmental Program
Yescarta Developmental Program
Global CAR-T Cell Therapies under Development
Recent Acquisitions in CAR T cell Market (2018)
Recent Collaborations in CAR T cell Market (2018)
CAR-T Cell Treatment Costs (2018)
Key Players - Revenue & Market Cap Comparison (2018)
Global CART Cell Therapies in AML under Development (2018)
Global CAR-T under Development for Metastatic Colorectal Cancer (2018)
Global BCMA CAR T Therapies in Clinical Trials for Multiple Myeloma (2018)
Global CD19 targeted CART products in Clinical Trials (2018)
Global CD19 targeted CART products in Clinical Trials for Adult ALL (2018)
